Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), a 44-amino-acid hypothalamic peptide that drives pulsatile growth hormone (GH) secretion from the anterior pituitary gland. The synthetic form retains the full GHRH(1–44) amino acid sequence with the addition of a trans-3-hexenoic acid group at the N-terminus, a structural modification that confers increased resistance to proteolytic degradation compared to native endogenous GHRH.
Tesamorelin acts upstream of GH itself — it engages GHRH receptors on anterior pituitary somatotrophs to stimulate GH secretion while preserving the physiological feedback regulation of the GH/IGF-1 axis. This distinguishes it from direct GH administration and from GH secretagogues that act via ghrelin receptors, such as those studied in CJC-1295 and Ipamorelin research.
This overview is educational and intended for researchers studying the somatotropic axis and its metabolic roles. It does not constitute medical advice.
Regulatory Background
Tesamorelin holds a uniquely well-documented position among peptide research compounds. It has completed regulated Phase 2, Phase 3, and long-term extension clinical trials enrolling hundreds of participants, culminating in FDA approval in November 2010 under the brand name Egrifta for the specific indication of reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
This approval is narrow and indication-specific. Outside the approved use, tesamorelin is an investigational compound studied by researchers examining the broader biology of the GH/IGF-1 axis, hepatic metabolism, and neurocognitive function. New Tech Science supplies tesamorelin for research use only and not for any clinical, therapeutic, or human consumption purpose.
Mechanism of Action
The somatotropic axis operates through a feedback loop between the hypothalamus, anterior pituitary, and liver. Hypothalamic GHRH stimulates pituitary somatotrophs to secrete GH in pulsatile bursts; GH then acts on the liver and peripheral tissues to produce IGF-1; IGF-1 exerts negative feedback on both the hypothalamus and pituitary. Somatostatin, an inhibitory hypothalamic peptide, provides a parallel suppressive checkpoint on GH secretion.
Tesamorelin engages this system by binding GHRH receptors on anterior pituitary somatotrophs, amplifying GH pulse amplitude in a manner that respects the natural pulsatile pattern and somatostatin-mediated inhibitory checkpoints. In the pivotal Phase 3 clinical trials, tesamorelin increased IGF-1 levels by approximately 100% above baseline, confirming robust downstream somatotropic activation (Falutz et al., 2010, JCEM, PMID 20554713).
HIV-Associated Lipodystrophy Research
The most extensive research record for tesamorelin concerns HIV-associated lipodystrophy, a condition in which antiretroviral therapy disrupts fat distribution and causes characteristic accumulation of visceral adipose tissue. The foundation of this research base is a 2007 Phase 2/3 randomized controlled trial (N=412) published in the New England Journal of Medicine. Tesamorelin reduced visceral adipose tissue by 15.2% from baseline versus a 5.0% increase in the placebo group over 26 weeks. Triglycerides decreased by approximately 50 mg/dL in the treatment arm versus a 9 mg/dL increase with placebo, and IGF-1 rose 81%. No clinically significant changes in fasting glucose were observed (Falutz et al., 2007, NEJM, PMID 18057338).
Subsequent international Phase 3 trials were pooled for a combined analysis of 806 participants. Tesamorelin at the studied dose for 26 weeks produced an approximately 24 cm² reduction in visceral adipose tissue versus a 2 cm² increase with placebo, alongside improvements in triglyceride and cholesterol ratios and patient-reported body image. Benefits were maintained through a 52-week safety extension, and this body of evidence formed the primary basis for FDA approval of Egrifta in November 2010 (Falutz et al., 2010, JCEM, PMID 20554713).
More recent work has confirmed efficacy in contemporary HIV treatment contexts. A 2024 sub-analysis published in AIDS evaluated tesamorelin specifically in patients receiving integrase inhibitor-based antiretroviral regimens — the predominant therapy type today — finding significant reductions in visceral fat and hepatic fat over 12 months with a comparable adverse event profile to earlier trials (Russo et al., 2024, AIDS, PMID 38905488). A 2026 meta-analysis synthesizing five RCTs confirmed significant reductions in visceral adipose tissue, trunk fat, hepatic fat percentage, and waist circumference, with no serious safety signals or glycemic disruption identified (Badran et al., 2026, Obes Res Clin Pract, PMID 41545261).
Non-Alcoholic Fatty Liver Disease Research
A separate line of research has examined tesamorelin’s effects on hepatic steatosis in HIV. A multicenter, double-blind RCT published in Lancet HIV (N=61) found that 12 months of tesamorelin produced a 4.1% absolute reduction in hepatic fat fraction compared to placebo, with 35% of tesamorelin recipients achieving liver fat below the 5% steatosis threshold versus only 4% of the placebo group (Stanley et al., 2019, Lancet HIV, PMID 31611038).
Mechanistic sub-studies using paired liver biopsies and transcriptomic analysis found that tesamorelin increased hepatic expression of oxidative phosphorylation gene sets while reducing expression of pathways associated with inflammation, fibrosis-related tissue repair, and aberrant cell division (Fourman et al., 2020, JCI Insight, PMID 32701508). Parallel proteomic work identified CSF1 (macrophage colony-stimulating factor) as a potential mediator of tesamorelin’s anti-fibrotic effects, with reductions in VEGFA, TGFB1, and CSF1 correlating with improved NAFLD activity and fibrosis scores (Fourman et al., 2021, Sci Rep, PMID 34006921). A third analysis found tesamorelin significantly decreased 13 circulating immune activation proteins including CCL3, CCL4, IL-8, and T-cell cytotoxic molecules, with parallel suppression observed in liver biopsy specimens (Stanley et al., 2021, Clin Infect Dis, PMID 33852720).
Metabolic Research in Non-HIV Populations
Researchers have also examined tesamorelin’s metabolic effects outside the HIV setting. A 2012 RCT published in the Journal of Clinical Endocrinology and Metabolism enrolled 60 abdominally obese non-HIV adults with reduced GH secretion. Tesamorelin significantly reduced visceral adipose tissue and improved triglycerides, C-reactive protein (CRP), and carotid intima-media thickness (cIMT) compared to placebo — without affecting subcutaneous adipose tissue or glucose metabolism (Makimura et al., 2012, JCEM, PMID 23015655). Carotid intima-media thickness is a validated surrogate marker for cardiovascular risk, making this a notable data point for investigators studying the metabolic consequences of GH axis dysregulation in obesity — an area with thematic parallels to mitochondrial metabolic research such as MOTS-c research.
Cognitive Function Research
A distinct body of research has examined the GHRH axis and neurocognition using tesamorelin as the investigational tool. A controlled trial published in Archives of Neurology enrolled 152 adults aged 55–87, including 66 with mild cognitive impairment (MCI), who received daily tesamorelin or placebo for 20 weeks. Tesamorelin produced favorable effects on cognition overall, with the strongest benefits observed in executive function domains — specifically task switching, interference processing, and verbal fluency. IGF-1 levels rose 117% and body fat decreased 7.4% in the treatment group. Adverse events were more frequent with tesamorelin (68% vs. 36%) (Baker et al., 2012, Arch Neurol, PMID 22869065).
A neuroimaging sub-study from the same cohort used magnetic resonance spectroscopy in 30 participants and found that 20 weeks of tesamorelin increased gamma-aminobutyric acid (GABA) levels across measured brain regions and elevated N-acetylaspartylglutamate (NAAG) in the frontal cortex. The authors described this as the first evidence that somatotropic supplementation modulates inhibitory neurotransmitter levels in a clinical trial setting, providing a neurobiological mechanism to explain the executive function improvements observed in the parent trial (Friedman et al., 2013, JAMA Neurology, PMID 23689947).
Research in HIV populations has produced more mixed results. A 2025 RCT in 73 HIV-positive individuals with abdominal obesity observed a trend toward improved neurocognitive performance that did not reach statistical significance over six months (Ellis et al., 2025, J Infect Dis, PMID 39813152), indicating that this remains an active and unresolved area of investigation. This parallels ongoing research into other pathways affecting neuronal energy metabolism, including NAD+ and its role in cellular energy pathways.
Ongoing Research Directions
Active investigation continues to expand the research scope of tesamorelin. The TRIUMPH clinical trial protocol, registered and published in BMJ Open in 2026, is enrolling 100 sedentary HIV-positive adults aged 50–80 to examine tesamorelin as an adjunct to home-based exercise for improving physical function in individuals at frailty risk. Endpoints include functional performance, muscle characteristics (including mitochondrial function assessed via biopsy), quality of life measures, and exercise adherence over 48 weeks (Erlandson et al., 2026, BMJ Open, PMID 42419889). This represents a current research frontier combining somatotropic augmentation with exercise intervention in aging populations with metabolic burden.
Safety Profile from Clinical Research
Across the clinical trial record, the most commonly documented adverse events with tesamorelin include administration-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia. The pooled Phase 3 analysis and the 2026 meta-analysis both found no clinically meaningful disruption to glucose metabolism or HbA1c at the doses studied (Falutz et al., 2010, JCEM, PMID 20554713; Badran et al., 2026, Obes Res Clin Pract, PMID 41545261). The 52-week extension data reviewed during the FDA approval process identified no new safety signals beyond those observed at 26 weeks. Researchers reviewing tesamorelin for laboratory purposes should consult the primary trial literature for complete adverse event profiles and context-specific safety data.
Research Supply
New Tech Science supplies tesamorelin as a research compound for qualified laboratory investigators. This product is for research use only and is not intended for human or animal use outside of formally regulated research protocols. Researchers should consult current scientific literature and applicable institutional review guidelines when designing studies involving GHRH analogs.
This article is for educational and research discussion purposes only. It does not constitute medical advice, treatment recommendations, or endorsement of any application outside of formally approved and regulated research contexts.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370. https://doi.org/10.1056/NEJMoa072375 (PMID 18057338)
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291–4304. https://doi.org/10.1210/jc.2010-0490 (PMID 20554713)
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240–247. https://doi.org/10.1345/aph.1Q629 (PMID 22298602)
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420–1429. https://doi.org/10.1001/archneurol.2012.1970 (PMID 22869065)
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism. 2012;97(12):4769–4779. https://doi.org/10.1210/jc.2012-2794 (PMID 23015655)
- Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology. 2013;70(7):883–890. https://doi.org/10.1001/jamaneurol.2013.1425 (PMID 23689947)
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8 (PMID 31611038)
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. https://doi.org/10.1172/jci.insight.140134 (PMID 32701508)
- Stanley TL, Fourman LT, Wong LP, et al. Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease. Clinical Infectious Diseases. 2021;73(4):621–630. https://doi.org/10.1093/cid/ciab019 (PMID 33852720)
- Fourman LT, Stanley TL, Billingsley JM, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports. 2021;11(1):10485. https://doi.org/10.1038/s41598-021-89966-y (PMID 34006921)
- Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758–1764. https://doi.org/10.1097/QAD.0000000000003965 (PMID 38905488)
- Ellis RJ, Vaida F, Hu K, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. Journal of Infectious Diseases. 2025;231(5):1230–1238. https://doi.org/10.1093/infdis/jiaf012 (PMID 39813152)
- Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obesity Research and Clinical Practice. 2026;20(1):2–12. https://doi.org/10.1016/j.orcp.2026.01.002 (PMID 41545261)
- Erlandson KM, Gustafson L, Johnson JE, et al. Tesamorelin as an adjunct to exercise for improving physical function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026;16(7):e120740. https://doi.org/10.1136/bmjopen-2026-120740 (PMID 42419889)
